6:33 PM
 | 
Dec 17, 2012
 |  BC Extra  |  Company News

Evotec grants J&J unit rights to NMDA portfolio

Evotec AG (Xetra:EVT) granted Janssen Pharmaceuticals Inc. exclusive, worldwide rights to develop and commercialize Evotec's portfolio of oral small molecule NMDA receptor NR2B subtype antagonists for depressive disorders. Evotec...

Read the full 135 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$35 USD
More Info >